|Bid||21.79 x 1300|
|Ask||21.80 x 900|
|Day's range||19.82 - 22.13|
|52-week range||1.92 - 33.79|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for breaches of fiduciary duties and violations of the Securities Exchange Act of 1934. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company’s shares between February 14, 2020 and March 9, 2020, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Pennsylvania.
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the "Class Period"). The case is captioned McDermid v. Inovio Pharmaceuticals, Inc., No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The Inovio Pharmaceuticals securities class action lawsuit charges Inovio Pharmaceuticals ("Inovio") and its current Chief Executive Officer J. Joseph Kim ("Kim") with violations of the Securities Exchange Act of 1934.